B-peptide-crm197 conjugate    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
11Myasthenia2

11. Myasthenia    [ 226 clinical trials,   172 drugs,   (DrugBank: 45 drugs),   43 drug target genes,   118 drug target pathways]
Searched query = "Myasthenia", "MG"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 226 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-000323-27-NL
(EUCTR)
03/08/201718/04/2017A study to evaluate the efficacy of CV-MG01 (Myasterix), a therapy for Myasthenia gravisA Multi-center, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Myasthenia Gravis Active Targeted Immunotherapy CV-MG01 in Patients with Moderate to Severe Myasthenia Gravis - Myasterix Efficacy Phase 2/3 Study Myasthenia Gravis (MG) is a chronic neuromuscular disorder characterized by weakness and fatigability of skeletal muscles.The underlying defect is a decrease in the number of available acetylcholine receptors (AChRs) at neuromuscular junctions due to an antibody-mediated autoimmune attack.
MedDRA version: 19.1;Level: PT;Classification code 10028417;Term: Myasthenia gravis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: CV-MG01
INN or Proposed INN: Not applicable
Other descriptive name: T-peptide-CRM197 conjugate
INN or Proposed INN: Not applicable
Other descriptive name: B-peptide-CRM197 conjugate
CuraVac Europe SANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
66Phase 2;Phase 3Belgium;Netherlands
2EUCTR2017-000323-27-BE
(EUCTR)
19/06/201713/04/2017A study to evaluate the efficacy of CV-MG01 (Myasterix) in Myasthenia GravisA Multi-center, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Myasthenia Gravis Active Targeted Immunotherapy CV-MG01 in Patients with Moderate to Severe Myasthenia Gravis - Myasterix Efficacy Phase 2/3 Study Myasthenia Gravis (MG) is a chronic neuromuscular disorder characterized by weakness and fatigability of skeletal muscles.The underlying defect is a decrease in the number of available acetylcholine receptors (AChRs) at neuromuscular junctions due to an antibody-mediated autoimmune attack.
MedDRA version: 19.1;Level: PT;Classification code 10028417;Term: Myasthenia gravis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: CV-MG01
INN or Proposed INN: Not applicable
Other descriptive name: T-peptide-CRM197 conjugate
INN or Proposed INN: Not applicable
Other descriptive name: B-peptide-CRM197 conjugate
CuraVac Europe SANULLNot RecruitingFemale: yes
Male: yes
66Phase 2;Phase 3Belgium;Netherlands